Pancreas Adenocarcinoma Clinical Trial
Official title:
The βIG-H3 Protein: a New Marker in PANCreatic Adenocarcinoma
The primary objective of this trial is to evaluate the correlation between the intensity of the protein big-h3 expression at tumoural microenvironment and the TNM/UICC staging (from I to IV) of pancreatic adenocarcinoma lesion.
The pancreatic adenocarcinoma is the most common pancreatic cancer. Currently, it represents the fourth cause of death by cancer in France. The diagnosis is often realized when the disease is at an advanced stage because of its delayed clinical expression. Only 20% of the patients are diagnosed at a stage enabling a tumour resection. Scientists discovered a protein playing a key role: the βig-h3 protein. In mouse models, this protein is present in several stages of the tumorigenesis. A mutation of the gene Kras leads to the development of PANin (Pancreatic Intraepithelial Neoplasia) type precancerous lesions. The βig-h3 protein is early and highly expressed in the stroma around these lesions and in the pancreatic adenocarcinoma stroma. Moreover, studies showed that protein neutralization leads to a tumour size reduction by increasing the CD8+anti-tumor activity. This protein is detected in the blood serum of patients suffering from a pancreatic adenocarcinoma. So, this protein which is secreted by the extracellular matrix could be a predictive marker for the pancreatic adenocarcinoma. In this prospective, multicentric non-interventional study, it is anticipated to recruit 80 patients (20 per TNM/UICC stage). Included patients will undergo two samples: A blood sample (5 ml) and a tumour sample (surgical exeresis piece or tumour tissue obtained for the initial diagnosis). In case of relapse, new samples will be performed. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06065891 -
Para-aortic Lymph Node Metastasis in Resectable Pancreatic Cancer
|
N/A | |
| Recruiting |
NCT05351983 -
Patient-derived Organoids Drug Screen in Pancreatic Cancer
|
N/A | |
| Completed |
NCT01774162 -
EUS-guided Fine Needle Biopsy With a New Core Histology Needle Versus Conventional Fine Needle Aspiration
|
N/A | |
| Recruiting |
NCT04164602 -
The Occurence of Pancreatic Cancer Studied in Association With Newly Diagnosed Diabetes in the Elderly
|
||
| Recruiting |
NCT05325281 -
CPI-613 (Devimistat) in Combination With Chemoradiation in Patients With Pancreatic Adenocarcinoma
|
Phase 1 | |
| Completed |
NCT05161013 -
A Proof-of-Concept Study Evaluating LINFU™
|
N/A | |
| Recruiting |
NCT05470920 -
Genetic Testing Decision Aid
|
N/A | |
| Recruiting |
NCT04099134 -
PACAREG: a Multicenter Registry Trial in Pancreatic Ductal Adencarcinoma
|
||
| Recruiting |
NCT05518071 -
FLUOPANC-trial - Fluorescence-guided Surgery of Pancreatic and Bileduct Tumors Using cRGD-ZW800-1
|
Phase 2 | |
| Withdrawn |
NCT04045730 -
The Study of Gemcitabine Plus Nab-Paclitaxel in Combination With Pegvorhyaluronidase Alfa (PVHA; PEGPH20) and Pembrolizumab as Front-line Treatment for Metastatic Pancreatic Adenocarcinoma.
|
Phase 2 | |
| Recruiting |
NCT06160596 -
Analyzing and Solving Exceptional Long-term Survivors in Solid Tumors With Poor Prognosis
|
||
| Recruiting |
NCT04636788 -
Circulating Extracellular Exosomal Small RNA as Potential Biomarker for Human Pancreatic Cancer
|
N/A | |
| Recruiting |
NCT04435067 -
Evaluation of Clinical, Radiomics and Molecular Features of Lung Metastasis in PDAC Patients (LUMACA Trial)
|
||
| Recruiting |
NCT04571294 -
Para-aortic Lymphnodes Removal During Upfront Pancreaticoduodenectomy
|
N/A | |
| Completed |
NCT03532347 -
Endoscopic Ultrasound Guided Tissue Sampling (The SharkBITE Study)
|
N/A | |
| Withdrawn |
NCT06090318 -
Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT06381882 -
The Role of the Human Microbiome in Patients After Pancreatic Resection.
|
||
| Recruiting |
NCT03544255 -
Drug Screening of Pancreatic Cancer Organoids Developed From EUS-FNA Guided Biopsy Tissues
|
||
| Recruiting |
NCT05340569 -
Diagnostic Value of DWI-MRI for Detection of Peritoneal Metastases in High-risk Pancreatic Ductal Adenocarcinoma.
|
N/A | |
| Active, not recruiting |
NCT04241367 -
Verification of Predictive Biomarkers for Pancreatic Cancer Treatment Using Multicenter Liquid Biopsy
|